patients with t2d presenting with glycosuria: examining the sglt2 moa
DESCRIPTION
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA. Goals. Diagnosed Diabetes, 1958-2010. Despite Increasing Prevalence, T2D Remains Undertreated. Limitations of Conventional Glucose-Lowering Agents. Limitations of Conventional Glucose-Lowering Agents (cont). - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/1.jpg)
Patients With T2D Presenting With Glycosuria: Examining the
SGLT2 MOA
![Page 2: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/2.jpg)
![Page 3: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/3.jpg)
Goals
![Page 4: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/4.jpg)
Diagnosed Diabetes, 1958-2010
![Page 5: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/5.jpg)
Despite Increasing Prevalence, T2D Remains Undertreated
![Page 6: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/6.jpg)
Limitations of Conventional Glucose-Lowering Agents
![Page 7: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/7.jpg)
Limitations of Conventional Glucose-Lowering Agents (cont)
![Page 8: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/8.jpg)
The Need for Novel Antihyperglycemic Agents
![Page 9: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/9.jpg)
Pathophysiologic Pathways Affecting Glycemic Control in
T2D
![Page 10: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/10.jpg)
SGLT2 and Glucose Control
![Page 11: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/11.jpg)
SGLT2: Novel Target for Glucose Control
![Page 12: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/12.jpg)
Currently FDA-approved SGLT2 Inhibitors
![Page 13: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/13.jpg)
Glycosuria: Concerns in Urgent Care Settings
![Page 14: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/14.jpg)
Clinical Trial Findings for SGLT2 Inhibitors
![Page 15: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/15.jpg)
Clinical Trial Findings for SGLT2 Inhibitors: Extraglycemic Effects
![Page 16: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/16.jpg)
![Page 17: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/17.jpg)
![Page 18: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/18.jpg)
SGLT2 Inhibitors: Risk of Hypotension
![Page 19: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/19.jpg)
![Page 20: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/20.jpg)
Treating Patients With Type 2 Diabetes and CKD
![Page 21: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/21.jpg)
![Page 22: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/22.jpg)
![Page 23: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/23.jpg)
Abbreviations
![Page 24: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/24.jpg)
Abbreviations (cont)
![Page 25: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/25.jpg)
References
![Page 26: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/26.jpg)
References (cont)
![Page 27: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/27.jpg)
References (cont)
![Page 28: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/28.jpg)
References (cont)
![Page 29: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/29.jpg)
References (cont)
![Page 30: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/30.jpg)
References (cont)
![Page 31: Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA](https://reader035.vdocuments.net/reader035/viewer/2022062308/56812d10550346895d91eb45/html5/thumbnails/31.jpg)
References (cont)